We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Clinical Trial With Bupivacaine Lozenges as Local Anaesthesia Under Upper Gastrointestinal Endoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01832675
Recruitment Status : Completed
First Posted : April 16, 2013
Last Update Posted : April 16, 2013
Oracain II Aps
Information provided by (Responsible Party):
Ove Andersen, Hvidovre University Hospital

Brief Summary:
In this project the investigators want to compare a new anaesthetic method during upper gastroscopic endoscopy, compared to the traditional used method in a private clinic. The new method is a lozenge containing bupivacaine, and the traditional method is a lidocaine spray.

Condition or disease Intervention/treatment Phase
Application Site Discomfort Drug: Xylocain, cutaneous spray, solution Drug: Bupivacaine lozenge Phase 2

Detailed Description:

The research group has previously conducted a clinical study with patients who underwent an UGE at the Department of Gastroenterology, Hvidovre University Hospital, Denmark, where the effect of a new lidocaine lozenge was compared to the lidocaine suspension that was used as standard treatment. The results showed that the lozenge increased the patient's acceptance of the gag reflexes, decreased the patient discomfort during UGE and thereby increased patient acceptance of the UGE. Furthermore, there was a significant improvement in assessment of taste and texture of the lozenge compared to the suspension. A study by Thanvi et al. has shown that it is difficult to obtain valid VAS scores when the patients are sedated, as it might cause amnesia and may impair the patient's ability to make an accurate assessment of the discomfort. Sedation were a limitation for the study conducted by the research group, because of impairment in the patients judgmental abilities. Furthermore a longer duration of the effect of the lozenge was requested. Therefore, the research group reformulated the lozenge and changed the active pharmaceutical ingredient (API) to bupivacaine. Bupivacaine is an amide as lidocaine, but has a longer anesthetic effect and is four times as potent as lidocaine. It would therefore be relevant to optimize the study design and perform a new clinical study with unsedated patients undergoing UGE, where the bupivacaine lozenge was tested.

The clinical study was performed in the private gastrointestinal (GI) clinic at Hvidovre, Denmark. Before the UGE was performed the patient was locally anesthetized in the pharynx with a lidocaine spray as a standard treatment.

The hypothesis was that a bupivacaine lozenge would reduce the patient experienced discomfort during UGE due to a better local anesthetic effect compared to lidocaine spray. Moreover it is hypothesized that the bupivacaine lozenge would be more patient friendly than the lidocaine spray because of a better taste masking according to lesser bitter taste and a pleasant mode of being anesthetized.

The aim of the study was to compare patient discomfort by two different local anesthetic methods. The standard treatment was a lidocaine pharyngeal spray and was compared to the experimental treatment a bupivacaine lozenge. The efficacy and acceptance of the treatments were also examined, as well as the taste of the anesthetics. Furthermore the patient's and endoscopist's assessment of the UGE was examined.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: New Bupivacaine Lozenge as Topical Anesthesia Compared to Lidocaine Pharyngeal Spray Before Upper Gastrointestinal Endoscopy in Unsedated Patients
Study Start Date : March 2012
Actual Primary Completion Date : August 2012
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Active Comparator: Bupivacaine lozenge
The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
Drug: Bupivacaine lozenge
25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.

Active Comparator: Xylocain, cutaneous spray, solution
The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
Drug: Xylocain, cutaneous spray, solution
10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.

Primary Outcome Measures :
  1. The patient experienced discomfort assessed on the Visual Analog Scale [ Time Frame: Day 1 ]
    The patient experienced discomfort during a upper gastroscopic endoscopy when using bupivacaine lozenge instead of lidocaine spray assessed on the Visual Analog Scale

Secondary Outcome Measures :
  1. Patient evaluation of taste and texture on a 3 point scale. - The investigator's assessment of the study by answering the questionnaire. [ Time Frame: Day 1 ]
    Patient evaluation of taste and texture of the lozenge or the spray on a 3 point scale.

  2. Endoscopist evaluation on a 4 point scale. [ Time Frame: Day 1 ]
    The endoscopist evaluate the difficulty of the upper gastrointestinal endoscopy on a 4 point scale.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Referral from personal doctor for the upper gastroscopic endoscopy
  • Age between 18 and 80 year
  • Able to speak, read and understand the danish language
  • Must be informed orally and released a written consent and a signed authorization statement

Exclusion Criteria:

  • Known allergy to bupivacaine or other local anesthetics of the amide type.
  • Pregnancy - the patient will be asked if she uses sufficient contraception. When in doubt a pregnancy test will be performed.
  • Breastfeeding
  • Use of other medicine before the examination besides the experimental medicine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01832675

Layout table for location information
Kirurgisk Klinik Hvidovre
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Ove Andersen
Oracain II Aps
Layout table for investigator information
Principal Investigator: Kaare Nielsen, MD Kirurgisk Klinik Hvidovre
Layout table for additonal information
Responsible Party: Ove Andersen, MD, PhD, Hvidovre University Hospital
ClinicalTrials.gov Identifier: NCT01832675    
Other Study ID Numbers: 2011-0056-22-21
First Posted: April 16, 2013    Key Record Dates
Last Update Posted: April 16, 2013
Last Verified: April 2013
Keywords provided by Ove Andersen, Hvidovre University Hospital:
Anesthetics, Local
Additional relevant MeSH terms:
Layout table for MeSH terms
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents